General communications


COVID-19 vaccine Comirnaty from Pfizer/BioNTech: Information for healthcare professionals concerning the sixth vaccine dose

Corona vaccine Comirnaty® (BNT162b2) from Pfizer/BioNTech: up to 6 doses per vial possible


Information about electronic pharmacovigilance reports

The required tools have been available for years


Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland

Vaccine from Pfizer/BioNTech authorised in the rolling review procedure after close scrutiny of the risks and benefits


ICMRA statement on the continuation of clinical trials

ICMRA recommends continued follow-up of study subjects in clinical trials of the SARS-CoV2 vaccine


Janssen-Cilag AG applies to have its vaccine candidate authorised

Swissmedic is examining Janssen’s COVID-19 vaccine in a rolling submission procedure


Access Consortium statement on COVID-19 vaccines evidence

The medicines regulators within the Access Consortium will only authorise vaccines if their benefits outweigh the risks


Aufsichtsabgabe 2020 – Selbstdeklaration

Eingabefrist: 22. Januar 2021


Interruption of production at Swiss contract manufacturer may temporarily disrupt supplies

Swissmedic inspection uncovers Good Manufacturing Practice (GMP) deficiencies

Last modification 29.03.2020

Top of page